Abin da Amincewar Isembyld Ainihin Sigina Game da Shirye-shiryen Kera Magungunan Peptide
Shirye-shiryen masana'antu na peptide warkewa, ba bayanan asibiti ba, yanke shawarar sakamakon ka'idoji guda biyu na kwayoyin halitta guda. FDA ta amince da Isembyld (apitegromab-mstn) kan 11 Satumba 2026 ga kashin baya muscular atrophy a manya da yara masu shekaru 2 kuma tsofaffi akan maganin SMN2 da aka yi niyya. Kwanaki ashirin da tara a baya, an janye aikace-aikacen EU.
Kasawar ta zo ta farko. A watan Satumba 2025 FDA ta ba da cikakkiyar wasiƙar amsawa tana ambaton matsalolin yarda a masana'anta na ɓangare na uku, tare da adawa da cewa mai alaƙa da rukunin masana'anta kuma ba ga inganci ko bayanan aminci ba. Bayanin Isembyld na EMA ya rubuta janyewar akan 13 Agusta 2026: shafin bai nuna yarda da EU GMP ba a cikin iyakar lokacin da ake buƙata. Bayan An Nuna Ayyukan Aiki na Hukuma, mai daukar nauyin ya watsar da wannan rukunin yanar gizon daga aikace-aikacen Amurka, kuma FDA ta amince.
Gyara daya kafin darasi. ISEMBYLD shine cikakken ɗan adam IgG4 antibody wanda ke ɗaure promyostatin da latent myostatin., ba peptide roba ba. Sanarwa ta FDA ba ta taɓa yin amfani da yaren yanayi kwata-kwata. Abin da ke canzawa zuwa peptide da abubuwan da suka danganci peptide shine horo na shirye-shirye, ba kwayoyin halitta ba.
Me yasa Shirye-shiryen Yanar Gizo ya yanke shawarar Samun Kasuwa Kafin Kimiyyar ta yi
The 2025 cikakkiyar wasiƙar amsa ba ta yi tambaya ba ko magani yayi aiki. Ya ba da misali da matsalolin bin doka a masana'anta na ɓangare na uku, wanda kamfanin ya bayyana yana da alaƙa da rukunin masana'anta maimakon ga inganci ko bayanan aminci (Asusun BioSpace na yarda).
Sunan rukunin yanar gizon da ake tambaya kawai a waje da shafukan mai gudanarwa kawai. Bayanin Isembyld na EMA bai gano wurin ba, yayin da GMP-binciken yarda da janyewar yana nuna samfurin Catalent Indiana na magunguna da kayan aikin cikawa, ambato a 2025 Wasikar Gargaɗi na FDA da a 2026 Siffar 483 rufe tushen-salin bincike, rashin haihuwa da gurbacewa, kafofin watsa labarai sun cika, kasadar tsayawa, da duban gani.
Ƙididdiga ita ce hujja. Kusan watanni goma sha ɗaya ne suka raba tushe daga ficewar EU, kusan watanni goma sha biyu zuwa amincewar Amurka, kuma 29 kwanaki tsakanin sakamakon biyu (Asusun BioSpace na yarda).
Don masana'antar GMP peptide, darasin yana canjawa wuri kai tsaye: cika-ƙasa ko rukunin samfuran magunguna waɗanda ba za su iya share binciken GMP haɗarin shiga kasuwa ne mai zaman kansa da yadda tsabtar API ɗin take..
Dabarun Kula da Sifa guda shida don Shirye-shiryen Samar da Magungunan Peptide
Ɗauki waɗannan sifofi guda shida azaman dabarun sarrafa nazari ɗaya, ba akwati shida ba. Shaida, tsabta da ƙazanta profile, tarawa da tsari mafi girma, iyawa, kwatanta bayan canji tsari, da saki gwajin kowanne yana takurawa sauran. Shirin da ke tabbatar da su a keɓance zai wuce kowane gwaji na mutum kuma har yanzu ya gaza kwatanta lokacin da tsari ya canza ƙasa.
Saitin sifa ba ƙirƙira ce ta musamman ta peptide ba. Magungunan peptide na iya faɗuwa cikin ɗaya ko fiye da nau'ikan tsari, a matsayin kwayoyin halitta na al'ada, halittu masu rai, ko biosimilars, da shirye-shiryen QC da aka rubuta musu suna suna halayen halayen halitta, tsari mafi girma, tarawa, disulfide-bond bincike, da kuma nazarin ƙazanta da ke da alaƙa da samfur a matsayin jerin halayen aiki (Abubuwan da BioProcess International ke ɗaukar nauyin abun ciki, 2020). Wannan jeri shine dalilin da ya sa tarawa da tsari mai girma ya kasance a nan: tunanin gama gari cewa ba sa amfani da peptides ya saba wa sifa da aka saita kanta.
Yi amfani da sassan da ke biyo baya don zana shirin ku. Kowannensu ya shafi dalilin da yasa sifa ta fi dacewa, yadda ake aiwatar da shi, me gazawa yayi kama da ita, da misalin aiki.
Tsarin rubutu: An ƙaddamar da wannan tsarin zuwa peptides ta kwatanci daga shari'ar antibody monoclonal. Misalin shine batun, ba da'awar da ta gabata ba.
Gwajin Shaida: Tabbatar da Jeri, Ba Kololuwa kawai ba
Babban kololuwa guda ɗaya a lokacin da ake tsammani ba ainihi ba. Gwajin shaidar Peptide yana yin tambaya daban fiye da amsoshi kashi dari: Wannan shine jerin da kuka gabatar, ko wani abu da kawai ya haɗa da shi?
Abubuwan ƙazanta waɗanda ke wuce rajistan kashi-kashi galibi suna ɗaukar sa hannun ƙayyadaddun jama'a. Bisa lafazin mai bayyana bayanin rashin tsarki na peptide, truncation ya bar ragowar N-terminal ya ɓace bayan rashin nasarar zagayowar haɗuwa, yayin da gogewa yana cire ragowar ciki kuma akai-akai yana haɗawa azaman kololuwar tauraron dan adam. Oxidation yana canzawa taro ta +16 Da as Met-sulfoxide (Cika a +16/+32/+48 Da) kuma yawanci elutes 1 ku 3 mintuna kafin haka. Ragowar kariya suna ƙara t-Bu +56 Da or Fmoc +222 Da, kuma pGlu yana zaune a -17/-18 Da.
Diastereomers suna karya muhawarar gaba daya: sun yi daidai a cikin taro da lakabin peptide. Abin da ya sa tabbatar da taro kadai bai isa ba kuma chromatographic orthogonality yana aiki na gaske.
Haɗa HPLC mai juyowa (Farashin RP-HPLC) tare da LC-MS/MS (ruwa chromatography-tandem mass spectrometry), sannan ƙara matakin zaɓi na chiral ko orthogonal a duk inda haɗarin diastereomer ya kasance na gaske.
Yanayin gazawar yayi shiru: ƙayyadaddun ƙayyadaddun sakin da ke wuce kashi ɗaya cikin ɗari yayin da tauraron dan adam mai gogewa ya wuce zuwa asibiti.
Bayanin Tsafta da Tsafta: Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwaƙwalwa
Nauyin najasa a cikin peptide na roba an saita shi sosai kafin a fara tsarkakewa, saboda kowane zagayowar haɗaɗɗiya yana barin ɗan guntun sarƙoƙi a baya. Mai ba da bayanin bayanin rashin tsarki na peptide ya ba da rahoton RP-HPLC kowace-zagaye na SPPS ingantaccen haɗin gwiwa na 99.0-99.8%, kuma lura cewa a 99.5% kowane zagaye akan 25-mer, kusan 12% na tara yawan amfanin ƙasa ya ɓace, wani sashe na wanda ya bayyana a matsayin tsattsauran ra'ayi (Lyochem Lab Bayanan kula, 2026-05-25). Wannan tushen mai siyarwa ne da ke bayanin aikin siffata kansa, don haka ɗauki kewayon azaman ƙwarewar aiki ɗaya maimakon masana'antu akai-akai.
Madogarar guda ta buga madaidaitan ICH Q3A-madaidaitan ƙofofin bayar da rahoto na yawanci 0.05% a matsakaicin adadin yau da kullun na 2 g/rana ko kasa da haka, da ƙofofin ganowa na yawanci 0.10-0.15% (Lyochem Lab Bayanan kula, 2026-05-25). Tabbatar da duka biyun akan rubutun ICH Q3A na farko kafin rubuta su cikin ƙayyadaddun bayanai.
Key Takeaway： Yanayin gazawar anan shine tsaftar peptide da ƙayyadaddun bayanan ƙazanta waɗanda aka gina akan madaidaicin kofa babu wanda ya bincika akan farkon rubutun ICH. Tabbatar da iyakoki na rahotanni na yanzu da ganowa a tushen, sannan saita iyakokin ku akan ainihin ingancin kowane zagaye na hanyar ku.
Tari da Tsarin Tsarin Tsarin Mulki: Halayen Peptides sun yi kuskure
Tari da tsari mafi girma suna cikin dabarun sarrafa peptide tun daga farko, kuma suna zaton ba haka ba shine yanayin gazawar. Siffar sifa mai suna QC saita ga peptides a sarari ya haɗa da siffa ta biophysical, tsari mafi girma, tarawa, da kuma disulfide-bond bincike, wanda ke sanya ikon sarrafa peptide tare da ainihi da tsabta maimakon a bayansu (BioProcess International, abun ciki mai ɗaukar nauyi).
Matakin aiwatarwa shine waɗanne hanyoyin biophysical don cancanta, kuma wannan yana cikin cancantar hanyar ku maimakon aron antibody panel. Matsalolin ƙara su shine kankare: tsawon jerin, abun ciki na disulfide, da girman kowane shimfidar hydrophobic. Wani ɗan gajeren peptide na layi wanda babu cysteines da wuya yana buƙatar cikakken saiti. Tsayi mai tsayi tare da disulfides da yawa, ko tubalin ginin peptidic mai ɗauke da gaɓoɓin jiki, yayi, saboda conjugate yana canza yanayin haɗuwa.
Peptide Synthesis Yanayin gazawar lokaci ne. Gano abin tarawa ko daidaituwa yayin kwatantawa, bayan canjin tsari, kuma kayan aikin da zai warware shi ya riga ya tafi. Gina hanyar da aka saita kafin canji, ba bayan.
Ƙarfafa Assay: Zaɓan Hanyar da Ta Rage Canjin Tsari
Zaɓi hanyar ƙarfi don azancinsa ga canjin da kuke iya yi, ba don dacewarsa wajen yin rajista ba. Ƙididdigar ƙarfin peptide wanda kawai ke tabbatar da kwayar halitta yana nan ba zai iya ɗaukar hujjar kwatantawa ba bayan wani shafi ko canjin sikelin., saboda ba a taɓa gina shi don yin rajistar canjin da kuke buƙatar bayyanawa yanzu ba.
Karatun da ke da alaƙa da injin shine wurin farawa. Gwajin tushen tantanin halitta ko ɗaure ya kamata ya auna matakin da canjin tsarin ku zai fi damuwa, ko wannan aikin haɗin gwiwa ne, mataki nadawa, ko kazanta da ke gasa a wurin da aka sa a gaba. Haɗa shi tare da ma'aunin tunani wanda cancantarsa ya riga ya canza, kuma rubuta dalilin yarda da ma'auni kafin ingantaccen lokaci-dace maimakon bayan rukunin farko ya gaza.
Yanayin gazawa shine bambancin faɗin isa don haɗiye tasiri na gaske. Idan amo na assay na kansa ya fi girma fiye da ƙarfin ƙarfin canjin canjin sikelin yana haifar, raguwa na gaske yana karantawa azaman bambancin al'ada, kuma kunshin kwatankwacin ba shi da siginar gardama daga.
Shirin da ke motsawa daga a 50 L zo a 500 L fermentation jirgin kasa nuna yadda wannan taka fita. Babban jirgin ruwa ya canza bayanin ƙazanta, amma ikon Peptides na roba hanyar ba ta taɓa samun cancantar gano wannan canjin ba, don haka ƙungiyar za ta iya nuna samfurin yana nan ba tare da iya nuna shi daidai ba.
Kwatanta Bayan Canjin Tsarin: Ƙididdigar Batch, Lokaci, da Rayuwar Rayuwa
Ayyuka Kwatanta bayan canjin tsari shine ƙidayar tsari da yanke shawara lokaci, kuma duka sassan biyu galibi suna yin latti don zama masu amfani. Daftarin kwatanta-bincike na FDA yana saita tsammanin aƙalla 3 gwada batches don ƙazanta, tarawa, da kwatankwacin rashin lafiyar jiki, a kalla 2 batches na miyagun ƙwayoyi a cikin samfurin gwaji, kuma a kalla 3 jeri-jerin magunguna batches na shekaru daban-daban (Takardar kwatancen FDA). Shafi ɗaya yana cikin shafi maimakon a cikin bayanin kula: wancan tushen PDF ne wanda rubutunsa ba a iya karanta shi da kansa ba a nan, don haka waɗannan alkalumman suna ɗauke da taƙaitaccen shafi na karanta kawai kuma yakamata a bincika su da takaddar farko kafin su shiga fayil ɗin da ke fuskantar ƙaddamarwa..
Gwajin da ke tsayawa a lokacin saki ya rasa yanayin lalacewa da canjin rukunin yanar gizon zai iya canzawa, don haka kunshin yana buƙatar sakin da bayanan ƙarshen-shilf-ray. Lokaci yana da mahimmanci kamar haka. Asusun BioSpace na yarda yana nuna abin da ke faruwa lokacin da matsalar rukunin yanar gizo ta bayyana bayan yin rajista: sai da shafin ya fito daga aikace-aikacen gaba daya. Samuwar Peptide
Don Tukwici: Alkaluman kirga na sama suna nan amma ba a tabbatar da kansu akan wannan dandali ba. Tabbatar da su a kan takaddun FDA na farko kafin buga su a cikin takardar da ke fuskantar ƙaddamarwa.
Gwajin Saki da Tushen Ka'idodin Motsawa
Tsammanin dabarun sarrafawa don ingantaccen peptides na roba suna cikin motsi har zuwa ranar amincewa, don haka ƙayyadaddun gwajin sakin peptide daskararre a yau na iya buƙatar sake yin aiki kafin a taɓa yin amfani da shi. Kunna 28 Yuli 2026, FDA ta buga 17 daftarin ƙayyadaddun jagororin samfur na wasu samfuran peptide na gabaɗaya kuma sun janye jagora guda ɗaya kamar yadda “ba a sake yin tunani ba.[ing] Tunanin kimiyya na FDA na yanzu,” da Bayanin FDA akan jagororin peptide da aka sabunta. Daftarin da aka cire shine Mayu 2021 synthetic-peptide jagora, kuma hukumar ta bayyana cewa tana shirin yin gyara tare da sake fitar da ita a bana, bisa lafazin sanarwar rajista na Tarayya.
The 17 ƙidaya yana da sauƙin karantawa. Lissafin sanarwar Rajista ta Tarayya 9 sinadaran aiki a baya wadanda 17 jagororin da aka bita: calcitonin salmon, dasiglucagon HCl, glucagon, liraglutide, pegcetacoplan, semaglutide, teriparatide, tirzepatide, da kuma vosoritide.
|
Daftarin da aka sabunta na PSGs |
Abubuwan da ke aiki da aka jera |
|---|---|
|
17 |
Shago 9 |
Ƙididdigar ta samfurin magani ne, ba ta hanyar sashi mai aiki ba.
Bi da jagorar da aka sake fitar a matsayin ƙayyadaddun ƙayyadaddun canji. Gina kwamitin sakin don haka canjin kofa baya bata tsarin tsarin gabaki ɗaya. Yanayin gazawa ginshiƙi ne da aka ƙera a kusa da zato na jagorar da aka janye.
Abin da Wannan Shari'ar Ke Yi kuma Ba Ya Koyar da Masu Haɓaka Peptide
Babban darasi da za a iya canjawa wuri daga shari'ar Isembyld shine cewa rukunin yanar gizon da ingantaccen shiri abu ne mai mahimmancin hanyar shigar da bayanai., ba damuwa aiki na ƙasa ba. Darussa hudu sun biyo baya daga haka, kuma daya gaskiya iyaka.
Cancantar rukunin yanar gizon kafin shigar da fayil. Likitan ya rasa aikace-aikacen sa na EU zuwa iyakar lokacin GMP maimakon ga bayanan sa, don haka aikin shirye-shiryen yana kan hanya mai mahimmanci, ba bayan shi.
Kada ka ɗauka tarawa da tsari mafi girma ba su da alaƙa da peptide. Sifa ce mafi yuwuwar ba a gina ta ba, kuma ana kiran shi a cikin saitin sifa na peptide QC.
Tabbatar da ƙididdige ƙididdiga da ƙididdige ƙididdiga akan takaddun farko. Rubutun na biyu yana kewaya lambobi waɗanda ba su tsira daga bincike akan tushen ba, wanda shine dalilin da ya sa wannan labarin ya keɓe saitin lambobi guda ɗaya mai kewayawa.
Bi da sifofi shida a matsayin dabarun sarrafawa ɗaya. Kwatancen shine inda shirye-shiryen sifa da aka katse suka kasa.
Iyaka: ISEMBYLD antibody ne na monoclonal, don haka wannan kwatancin shiri ne wanda aka shimfida zuwa peptides da abubuwan da suka danganci peptide, ba ma'anar yarda da peptide ba.
Mataki na gaba: ci naka shirin a kan shida halaye, sannan tabbatar da matakin yanzu da layin ƙidayar batch akan takaddun farko kafin ƙaddamar da ranar ƙaddamarwa. Canje-canje na MOL yana goyan bayan shirye-shiryen masana'anta na peptide na warkewa ta hanyar ingantaccen lokaci da haɗaɗɗun fermentation na ƙwayoyin cuta., Class 100 ayyuka masu tsabta, da HPLC, MS da haihuwa QC, kuma za a iya amfani da shi don yin bitar dabarun sarrafa nazari akan halayen da ke sama. Takamaiman yanke shawara na shirin na buƙatar ƙwararrun ƙwararrun tsari da ƙwararrun ƙwararru.
Tambayoyin da ake yawan yi
Shin wannan tsarin shirye-shiryen zai yi aiki don ƙaramin shirin peptide?
Ee, tare da kunshin shaida da aka matsa. Shirin ba tare da kwazo aikin CMC ba zai iya tafiyar da duk sifofi shida, amma yakamata ya dogara akan bayanan dandamali da aikin hanyar da aka buga maimakon samar da ingantaccen saiti na kowane sifa. Tsarin baya ɗaukar babban ƙungiya; yana ɗauka cewa gwajin shaidar peptide, tsarki, tarawa, iyawa, kwatanta, da gwajin saki kowanne yana da mai suna da kuma hanyar da aka rubuta, koda mutum daya ya rike da dama daga cikin wadancan matsayin. Yanayin rashin nasara ba ƙaramin ƙungiya ba ne. Siffa ce wacce ba ta da mai shi har sai lokacin da aka kammala gabatar da shi ya tilasta daya.
Menene fakitin kwatankwacin gaske farashi a batches da lokaci?
Kasafin kuɗi don gwajin saki da gwajin ƙarshen-tsaye akan duka abubuwan da suka rigaya da canji, wanda yawanci yana nufin aƙalla batches uku a kowane gefe da taga kwanciyar hankali da aka auna cikin watanni, ba makonni ba. Madaidaicin ƙidayar rukuni ya dogara da tsarin ku da mai sarrafa ku, don haka tabbatar da alkaluma a kan jagorar farko maimakon taƙaitawa. Yanayin gazawar anan shine jeri: ƙungiyoyi sukan fara canjin tsari kafin a rubuta ƙa'idar kwatanta, sannan gano hanyoyin bincike ba za su iya warware bambancin da suke buƙatar nunawa ba.
Me za ku yi dabam daga shari'ar Isembyld?
Cancantar shafin a baya, ayyana hanyar biophysical da aka saita kafin canji na farko, da karanta ƙofa a cikin takaddun farko maimakon cikin ɗaukar hoto. Tambayar rukunin yanar gizon ba cikakkun bayanai ba ne da ke warware kanta a makara; abu ne na gating wanda zai iya yanke shawarar shiga kasuwa ba tare da kimiyya ba. Kula da shirye-shiryen masana'antu na peptide na warkewa azaman matakin-shiri wanda za'a iya bayarwa, mallakar tun farko, shine bambanci tsakanin fayil ɗin da ke motsawa da wanda ke jira.
Kammalawa
Shirye-shiryen masana'antu na warkewa peptide ba aikin takaddun shaida bane da kuka kammala sau ɗaya; dabarun sarrafawa ne da kuke ci gaba da zira kwallaye. Shari'ar Isembyld tana yin hakan kankare. Kwayoyin halitta iri ɗaya, bita ta hanyar masu gudanarwa guda biyu, produced two outcomes, and the variable that moved was the site: the FDA had cited compliance problems at a third-party manufacturer, and the sponsor dropped that location from its application entirely (Asusun BioSpace na yarda). The EU application was withdrawn on 13 Agusta 2026 because the site had not demonstrated EU GMP compliance within the required time limit (EMA’s Isembyld overview). Twenty-nine days separate the two decisions. Game da
Score your own program against the six attributes and find the one you cannot yet evidence. That attribute sets your ceiling. Verify every threshold, batch count, and guidance citation against the primary document before it enters a submission-facing artifact.
One boundary worth restating: ISEMBYLD is a fully human monoclonal IgG4 antibody, ba peptide ba (the sponsor’s approval announcement). The control strategy transfers; tsarin bai yi ba.
Saka maki shirin ku kafin matakin shigar ku na gaba Kawo jerin rata na sifofi guda shida zuwa nazarin fasaha na dabarun sarrafa nazarin ku, rufe ainihi, tsarki, tarawa, iyawa, kwatancen da gwajin saki, kuma ku karanta inda shaidarku ta fi ƙanƙanta. Yi magana da gwani
Canje-canje na MOL yana ba da tallafin nazari da masana'antu don shirye-shiryen peptide. Yanke shawara game da takamaiman shirin warkewa na buƙatar ƙwararrun ƙwararrun tsari da ƙwararrun ƙwararru.
